Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Given Consensus Rating of “Buy” by Brokerages

Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTXGet Rating) have been given an average recommendation of “Buy” by the five ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $6.20.

A number of research analysts have weighed in on SGTX shares. Zacks Investment Research raised shares of Sigilon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Thursday, March 17th. cut their price target on shares of Sigilon Therapeutics from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, December 23rd.

Sigilon Therapeutics stock traded down $0.01 during midday trading on Friday, hitting $1.20. 196 shares of the stock were exchanged, compared to its average volume of 95,554. The company has a fifty day simple moving average of $1.43 and a two-hundred day simple moving average of $2.80. Sigilon Therapeutics has a 52 week low of $1.20 and a 52 week high of $16.71. The stock has a market capitalization of $38.88 million, a PE ratio of -0.50 and a beta of 0.86.

Sigilon Therapeutics (NASDAQ:SGTXGet Rating) last released its quarterly earnings data on Monday, March 14th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.09). The company had revenue of $1.99 million for the quarter, compared to analyst estimates of $3.80 million. On average, research analysts forecast that Sigilon Therapeutics will post -1.36 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Sigilon Therapeutics by 24.0% in the third quarter. BlackRock Inc. now owns 1,740,942 shares of the company’s stock valued at $9,837,000 after purchasing an additional 336,658 shares during the last quarter. Morgan Stanley raised its holdings in shares of Sigilon Therapeutics by 26,803.2% in the second quarter. Morgan Stanley now owns 546,942 shares of the company’s stock valued at $5,869,000 after purchasing an additional 544,909 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Sigilon Therapeutics by 10.7% in the third quarter. American Century Companies Inc. now owns 359,688 shares of the company’s stock valued at $2,033,000 after purchasing an additional 34,806 shares during the last quarter. State Street Corp raised its holdings in shares of Sigilon Therapeutics by 15.0% in the fourth quarter. State Street Corp now owns 260,809 shares of the company’s stock valued at $720,000 after purchasing an additional 34,088 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Sigilon Therapeutics by 73.2% during the third quarter. Geode Capital Management LLC now owns 231,662 shares of the company’s stock worth $1,308,000 after buying an additional 97,887 shares during the last quarter. Institutional investors own 57.63% of the company’s stock.

Sigilon Therapeutics Company Profile (Get Rating)

Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.

Further Reading

Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.